All products developed by BioMimetic Therapeutics are based upon recombinant human platelet-derived growth factor (rhPDGF-BB) platform technology. rhPDGF-BB is a synthetic copy of Platelet-Derived Growth Factor (PDGF), which is a naturally occurring protein. PDGF is released when platelets (blood cells involved with clotting) activate in response to injury. Upon release, PDGF activates a number of critical events essential for the initiation of musculoskeletal tissue repair.
rhPDGF-BB has the same functionality, potency and specificity as endogenous (natural) PDGF and is available in a well-characterized, purified and concentrated preparation. rhPDGF-BB is the active biological agent in two successfully marketed and FDA approved products†, both of which have an excellent safety profile.
BioMimetic is actively developing products based upon the potent regenerative capacity of rhPDGF-BB, to address unmet needs in the repair and treatment of bone, ligament, tendon and cartilage.
†Regranex®, indicated for the treatment of diabetic foot ulcers, is marketed by Systagenix Wound Management.
GEM21S®, indicated for the treatment of periodontal bone defects, was developed by BioMimetic Therapeutics and is marketed by Luitpold Pharmaceuticals.
 | 
